Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …

Next-generation sequencing (NGS) has been increasingly popular in genomics studies over
the last decade, as new sequencing technology has been created and improved. Recently …

Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-
risk disease. Here, we used a three-platform sequencing approach, including whole …

Simple Summary B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric
cancer. Even though the cure rate actually exceeds 85%, the prognosis of …

Genetic lesions predisposing to pediatric B-cell acute lymphoblastic leukemia (B-ALL) arise
in utero, generating a clinically silent pre-leukemic phase. We here reviewed the role of the …

Introduction The suitability of whole-genome sequencing (WGS) as the sole method to
detect clinically relevant genomic aberrations in B-cell acute lymphoblastic leukemia (ALL) …

Cure rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer have
steadily improved over the past five decades. This is due to intensifying systemic therapy …

Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …

The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by
recurrent, prognostic genetic alterations, many of which are cryptic by conventional …

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using
autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute …